PI3K Inhibitor Compound A for Lymphoproliferative Malignancies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lymphoproliferative malignancies, such as lymphomas and leukemias, face challenges with varying success rates and the development of treatment-refractory disease or relapse due to molecular escape mechanisms, necessitating the need for more effective therapeutic agents.
Innovation Solution
Administration of a therapeutically effective amount of Compound A, a specific pharmaceutical compound, or its pharmaceutically acceptable salt, which is a potent inhibitor of PI3Ks, to patients with lymphoproliferative disorders, including chronic lymphocytic leukemia and lymphomas, to inhibit tumor growth and prevent recurrence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current chemotherapeutic regimens are used to treat lymphoproliferative malignancies, then some treatment response is achieved, but treatment-refractory disease and relapse occur due to molecular escape mechanisms
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of PI3K inhibitors to optimize their binding affinity and selectivity. By systematically varying molecular parameters such as substituent groups on the quinoxaline core, the invention achieves improved inhibition of PI3K isoforms while overcoming resistance mechanisms that limit conventional chemotherapy effectiveness.
2Productivity
If various treatment modalities are administered to lymphoma patients, then initial treatment response is achieved, but patients develop treatment-refractory disease or relapse
Solution Approach 1:
The patent applies preliminary action by using PI3K inhibition to prevent the development of resistance and relapse before they occur. The compound A treatment is designed to maintain continuous suppression of the PI3K pathway, which drives lymphoma cell proliferation and survival, thereby preventing molecular escape and extending disease-free survival beyond what conventional chemotherapy can achieve.
3Reliability
If conventional chemotherapy regimens are used, then some malignancy control is achieved, but median overall survival remains limited at 4.8 years for MCL
Solution Approach 1:
The patent achieves improved overall survival by changing the therapeutic parameter from conventional chemotherapy to targeted PI3K inhibition. Compound A demonstrates potent and selective inhibition of PI3K isoforms, which directly addresses the molecular driver of lymphoma progression. This targeted approach overcomes the limitations of conventional chemotherapy and extends median overall survival beyond 4.8 years in mantle cell lymphoma patients.
Data Source
AI summary
Methods are provided for treating a lymphoproliferative malignancy to a patient in need of such treatment, comprising administering to the patient an effective amount of compound A as described herein.